| Document and Entity Information - USD ($) | 12 Months Ended | | |
| Dec. 31, 2022 | Apr. 06, 2023 | Jun. 30, 2022 |
| Cover [Abstract] | | | |
| Document Type | 10-K/A | | |
| Amendment Flag | true | | |
| Amendment Description | We are filing this Amendment No. 1 on Form 10-K/A to amend our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 30, 2023 (Original Filing), to include the information required by Part III of Form 10-K. The Part III information was previously omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference from our definitive proxy statement if such statement is filed no later than 120 days after our fiscal year-end. The information required by Items 10-14 of Part III is no longer being incorporated by reference to the proxy statement relating to our 2023 Annual Meeting of Shareholders. The reference on the cover of the Original Filing to the incorporation by reference to portions of our definitive proxy statement into Part III of the Original Filing is hereby deleted. This Amendment No. 1 is not intended to update any other information presented in the Original Filing. In addition, as required by Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act), new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by our principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment No.1. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. | | |
| Document Period End Date | Dec. 31, 2022 | | |
| Document Fiscal Year Focus | 2022 | | |
| Document Fiscal Period Focus | FY | | |
| Entity Registrant Name | Arcadia Biosciences, Inc. | | |
| Entity Central Index Key | 0001469443 | | |
| Entity Current Reporting Status | Yes | | |
| Current Fiscal Year End Date | --12-31 | | |
| Entity Filer Category | Non-accelerated Filer | | |
| Entity Voluntary Filers | No | | |
| Entity Well-known Seasoned Issuer | No | | |
| Entity Common Stock, Shares Outstanding | | 857,572 | |
| Entity Public Float | | | $ 21,027,600 |
| Stock price | | | $ 40 |
| Entity Listing, Par Value Per Share | $ 0.001 | | |
| Entity Shell Company | false | | |
| Entity Emerging Growth Company | false | | |
| Entity Small Business | true | | |
| Entity File Number | 001-37383 | | |
| Entity Tax Identification Number | 81-0571538 | | |
| Entity Address, Address Line One | 5950 Sherry Lane | | |
| Entity Address, Address Line Two | Suite 215 | | |
| Entity Address, City or Town | Dallas | | |
| Entity Address, State or Province | TX | | |
| Entity Address, Postal Zip Code | 75225 | | |
| City Area Code | 214 | | |
| Local Phone Number | 974-8921 | | |
| Entity Incorporation, State or Country Code | DE | | |
| Trading Symbol | RKDA | | |
| Title of 12(b) Security | Common | | |
| Security Exchange Name | NASDAQ | | |
| Entity Interactive Data Current | Yes | | |
| Document Annual Report | true | | |
| Document Transition Report | false | | |
| ICFR Auditor Attestation Flag | false | | |
| Documents Incorporated by Reference | None | | |
| Auditor Firm ID | 34 | | |
| Auditor Name | Deloitte & Touche LLP | | |
| Auditor Location | Tempe, AZ, United States | | |
